{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:22:09Z","timestamp":1771456929596,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"NICHD","doi-asserted-by":"publisher","award":["HD036071"],"award-info":[{"award-number":["HD036071"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"NICHD","doi-asserted-by":"publisher","award":["HD103526"],"award-info":[{"award-number":["HD103526"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MIND Institute IDDRC P50","award":["HD036071"],"award-info":[{"award-number":["HD036071"]}]},{"name":"MIND Institute IDDRC P50","award":["HD103526"],"award-info":[{"award-number":["HD103526"]}]},{"name":"The Victor LaFave III Fund, the Phillips Fund and the Tides Foundation","award":["HD036071"],"award-info":[{"award-number":["HD036071"]}]},{"name":"The Victor LaFave III Fund, the Phillips Fund and the Tides Foundation","award":["HD103526"],"award-info":[{"award-number":["HD103526"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Fragile X syndrome (FXS) is the leading inherited cause of intellectual disability (ID) and single gene cause of autism. Although most patients with FXS and the full mutation (FM) have complete methylation of the fragile X messenger ribonucleoprotein 1 (FMR1) gene, some have mosaicism in methylation and\/or CGG repeat size, and few have completely unmethylated FM alleles. Those with a complete lack of methylation are rare, with little literature about the cognitive and behavioral phenotypes of these individuals. A review of past literature was conducted regarding individuals with unmethylated and mosaic FMR1 FM. We report three patients with an unmethylated FM FMR1 alleles without any behavioral or cognitive deficits. This is an unusual presentation for men with FM as most patients with an unmethylated FM and no behavioral phenotypes do not receive fragile X DNA testing or a diagnosis of FXS. Our cases showed that mosaic males with unmethylated FMR1 FM alleles may lack behavioral phenotypes due to the presence of smaller alleles producing the FMR1 protein (FMRP). However, these individuals could be at a higher risk of developing fragile X-associated tremor\/ataxia syndrome (FXTAS) due to the increased expression of mRNA, similar to those who only have a premutation.<\/jats:p>","DOI":"10.3390\/genes15030331","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T05:31:12Z","timestamp":1709530272000},"page":"331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Unmethylated Mosaic Full Mutation Males without Fragile X Syndrome"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-8499","authenticated-orcid":false,"given":"YeEun","family":"Tak","sequence":"first","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA 95616, USA"},{"name":"Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA 95817, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4674-7244","authenticated-orcid":false,"given":"Andrea","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA 95817, USA"},{"name":"Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-7262","authenticated-orcid":false,"given":"Ellery","family":"Santos","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA 95616, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9936-7528","authenticated-orcid":false,"given":"Jamie Leah","family":"Randol","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-9180","authenticated-orcid":false,"given":"Flora","family":"Tassone","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA 95616, USA"},{"name":"Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1142-5680","authenticated-orcid":false,"given":"Paul","family":"Hagerman","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA 95616, USA"},{"name":"Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-8448","authenticated-orcid":false,"given":"Randi J.","family":"Hagerman","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA 95616, USA"},{"name":"Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA 95817, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1542\/peds.2016-1159F","article-title":"Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment","volume":"139","author":"Kaufmann","year":"2017","journal-title":"Pediatrics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ajmg.a.36511","article-title":"Epidemiology of fragile X syndrome: A systematic review and meta-analysis","volume":"164","author":"Hunter","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(91)90397-H","article-title":"Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome","volume":"65","author":"Verkerk","year":"1991","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41583-021-00445-9","article-title":"Channelopathies in fragile X syndrome","volume":"22","author":"Deng","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuron.2008.10.004","article-title":"Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function","volume":"60","author":"Bassell","year":"2008","journal-title":"Neuron"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tassone, F., Protic, D., Allen, E.G., Archibald, A.D., Baud, A., Brown, T.W., Budimirovic, D.B., Cohen, J., Dufour, B., and Eiges, R. (2023). Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation. Cells, 12.","DOI":"10.3390\/cells12182330"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fgene.2018.00529","article-title":"Fragile X Associated Primary Ovarian Insufficiency (FXPOI): Case Report and Literature Review","volume":"9","author":"Fink","year":"2018","journal-title":"Front. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajmg.a.62594","article-title":"The association between mosaicism type and cognitive and behavioral functioning among males with fragile X syndrome","volume":"188","author":"Meng","year":"2022","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/ajmg.a.37125","article-title":"High functioning male with fragile X syndrome and fragile X-associated tremor\/ataxia syndrome","volume":"167","author":"Basuta","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pandelache, A., Baker, E.K., Aliaga, S.M., Arpone, M., Forbes, R., Stark, Z., Francis, D., and Godler, D.E. (2019). Clinical and Molecular Differences between 4-Year-Old Monozygous Male Twins Mosaic for Normal, Premutation and Fragile X Full Mutation Alleles. Genes, 10.","DOI":"10.3390\/genes10040279"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1399-0004.2011.01675.x","article-title":"Fragile X-associated tremor\/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene","volume":"82","author":"Loesch","year":"2012","journal-title":"Clin. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/cge.12278","article-title":"FXTAS in an unmethylated mosaic male with fragile X syndrome from Chile","volume":"86","author":"Pugin","year":"2014","journal-title":"Clin. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2141516","DOI":"10.1001\/jamanetworkopen.2021.41516","article-title":"Prevalence of Underdiagnosed Fragile X Syndrome in 2 Health Systems","volume":"4","author":"Movaghar","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/ajmg.b.32176","article-title":"FMR1 CGG expansions: Prevalence and sex ratios","volume":"162","author":"Maenner","year":"2013","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GIM.0b013e3181d0d40e","article-title":"Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: Implications for fragile X syndrome carrier and newborn screening","volume":"12","author":"Hantash","year":"2010","journal-title":"Genet. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/gm401","article-title":"FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States","volume":"4","author":"Tassone","year":"2012","journal-title":"Genome Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/brain\/awh683","article-title":"Neuropathology of fragile X-associated tremor\/ataxia syndrome (FXTAS)","volume":"129","author":"Greco","year":"2006","journal-title":"Brain J. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1096-8628(20000918)94:3<232::AID-AJMG9>3.0.CO;2-H","article-title":"Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA","volume":"94","author":"Tassone","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cge.12026","article-title":"Fragile X-associated tremor\/ataxia syndrome (FXTAS) in grey zone carriers","volume":"84","author":"Liu","year":"2013","journal-title":"Clin. Genet."},{"key":"ref_20","first-page":"tre-02-56-352-1","article-title":"Fragile X-Associated Tremor Ataxia Syndrome: The Expanding Clinical Picture, Pathophysiology, Epidemiology, and Update on Treatment","volume":"2","author":"Hall","year":"2012","journal-title":"Tremor Hyperkinetic Mov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-9158-2-10","article-title":"Intranuclear inclusions in a fragile X mosaic male","volume":"2","author":"Pretto","year":"2013","journal-title":"Transl. Neurodegener."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1093\/hmg\/ddv165","article-title":"RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome","volume":"24","author":"Oh","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Salcedo-Arellano, M.J., Johnson, M.D., McLennan, Y.A., Hwang, Y.H., Juarez, P., McBride, E.L., Pantoja, A.P., Durbin-Johnson, B., Tassone, F., and Hagerman, R.J. (2023). Brain Metabolomics in Fragile X-Associated Tremor\/Ataxia Syndrome (FXTAS). Cells, 12.","DOI":"10.3390\/cells12172132"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fpsyt.2018.00564","article-title":"Fragile X-Associated Neuropsychiatric Disorders (FXAND)","volume":"9","author":"Hagerman","year":"2018","journal-title":"Front. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/mdc3.12449","article-title":"The Corpus Callosum Splenium Sign in Fragile X-Associated Tremor Ataxia Syndrome","volume":"4","author":"Hall","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2040-2392-3-5","article-title":"High-functioning autism spectrum disorder and fragile X syndrome: Report of two affected sisters","volume":"3","author":"Chaste","year":"2012","journal-title":"Mol. Autism"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/14737159.2017.1377612","article-title":"Size and methylation mosaicism in males with Fragile X syndrome","volume":"17","author":"Jiraanont","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuron.2013.03.026","article-title":"CGG Repeat-Associated Translation Mediates Neurodegeneration in Fragile X Tremor Ataxia Syndrome","volume":"78","author":"Todd","year":"2013","journal-title":"Neuron"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/hmg\/ddab353","article-title":"Mechanistic convergence across initiation sites for RAN translation in fragile X associated tremor ataxia syndrome","volume":"31","author":"Zhang","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e7371","DOI":"10.1002\/ccr3.7371","article-title":"High performing male with fragile X syndrome with an unmethylated FMR1 full mutation: The relevance of clinical and genetic correlations","volume":"11","author":"Shieh","year":"2023","journal-title":"Clin. Case Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1399-0004.2011.01723.x","article-title":"CGG repeat in the FMR1 gene: Size matters","volume":"80","author":"Willemsen","year":"2011","journal-title":"Clin. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41398-020-00863-w","article-title":"Elevated FMR1-mRNA and lowered FMRP\u2014A double-hit mechanism for psychiatric features in men with FMR1 premutations","volume":"10","author":"Schneider","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1373\/clinchem.2009.136101","article-title":"A Novel FMR1 PCR Method that Reproducibly Amplifies Fragile X Full Mutations in Concordance with Southern Blotting and Reliably Detects Low Abundance Expanded Alleles","volume":"56","author":"Sah","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kim, K., Hessl, D., Randol, J.L., Espinal, G.M., Schneider, A., Protic, D., Aydin, E.Y., Hagerman, R.J., and Hagerman, P.J. (2019). Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226811"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1096-8628(19960809)64:2<278::AID-AJMG9>3.0.CO;2-Q","article-title":"A fragile X male with a broad smear on southern blot analysis representing 100\u2013500 CGG repeats and no methylation at the EagI site of the FMR-1 gene","volume":"64","author":"Lachiewicz","year":"1996","journal-title":"Am. J. Med. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5582\/irdr.2014.01023","article-title":"Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases","volume":"3","author":"Muzar","year":"2014","journal-title":"Intractable Rare Dis. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1212\/01.wnl.0000168865.36352.53","article-title":"Fragile X-associated tremor\/ataxia syndrome presenting in a woman after chemotherapy","volume":"65","author":"Clabby","year":"2005","journal-title":"Neurology"},{"key":"ref_38","first-page":"1","article-title":"General Anesthetic Use in Fragile X Spectrum Disorders","volume":"31","author":"Ligsay","year":"2018","journal-title":"J. Neurosurg. Anesthesiol."},{"key":"ref_39","first-page":"1689","article-title":"Fragile X Premutation: Medications, Therapy and Lifestyle Advice","volume":"14","author":"Sodhi","year":"2021","journal-title":"Pharmacogenom. Pers. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2119\/molmed.2016.00122","article-title":"Altered Redox Mitochondrial Biology in the Neurodegenerative Disorder Fragile X-Tremor\/Ataxia Syndrome: Use of Antioxidants in Precision Medicine","volume":"22","author":"Song","year":"2016","journal-title":"Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hagerman, P.J., and Hagerman, R.J. (2020). Fragile X Syndrome and Premutation Disorders: New Developments and Treatments, Mac Keith Press. [1st ed.].","DOI":"10.1002\/9781119432692.ch28"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/3\/331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:41Z","timestamp":1760105321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/3\/331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["genes15030331"],"URL":"https:\/\/doi.org\/10.3390\/genes15030331","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]}}}